Bank of America
VTGN icon

Bank of America’s VistaGen Therapeutics VTGN Stock Holding History

Bank of America’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.75K Buy
+16,570
New +$9.99K ﹤0.01% 5657
2026
Q1 		– Sell
-3,145
Closed -$2.08K – 6898
2025
Q4 		$2.08K Sell
3,145
-31,512
-91% -$114K ﹤0.01% 6404
2025
Q3 		$123K Buy
34,657
+31,279
+926% +$93.5K ﹤0.01% 6511
2025
Q2 		$6.76K Buy
3,378
+2,701
+399% +$6.13K ﹤0.01% 7258
2025
Q1 		$1.69K Sell
677
-20,464
-97% -$57.9K ﹤0.01% 7357
2024
Q4 		$62.4K Buy
21,141
+19,331
+1,068% +$54.4K ﹤0.01% 6565
2024
Q3 		$5.45K Buy
1,810
+1,572
+661% +$5.36K ﹤0.01% 6993
2024
Q2 		$829 Sell
238
-9,891
-98% -$42.8K ﹤0.01% 7262
2024
Q1 		$53.5K Sell
10,129
-9,270
-48% -$44.6K ﹤0.01% 6493
2023
Q4 		$99.7K Buy
19,399
+18,766
+2,965% +$71K ﹤0.01% 6376
2023
Q3 		$3.32K Buy
633
+1
+0.2% +$4 ﹤0.01% 7067
2023
Q2 		$1.18K Sell
632
-2,110
-77% -$7.4K ﹤0.01% 7221
2023
Q1 		$10.2K Sell
2,742
-1,416
-34% -$7.42K ﹤0.01% 6912
2022
Q4 		$12.8K Sell
4,158
-10,587
-72% -$39.8K ﹤0.01% 6863
2022
Q3 		$67K Buy
14,745
+14,483
+5,528% +$144K ﹤0.01% 6545
2022
Q2 		$7K Sell
262
-4,907
-95% -$173K ﹤0.01% 7522
2022
Q1 		$192K Sell
5,169
-12,675
-71% -$553K ﹤0.01% 6495
2021
Q4 		$1.04M Buy
17,844
+17,816
+63,629% +$1.16M ﹤0.01% 5199
2021
Q3 		$2K Sell
28
-49
-64% -$4.26K ﹤0.01% 7912
2021
Q2 		$7K Buy
+77
New +$5.71K ﹤0.01% 7376
2019
Q4 		– Sell
-26
Closed -$1K – 7428
2019
Q3 		$1K Buy
+26
New +$579 ﹤0.01% 7141
2018
Q3 		– Hold
0
– – – 7486
2018
Q2 		– Hold
0
– – – 7348
2016
Q4 		– Sell
-2
Closed – – 7336
2016
Q3 		$0 Sell
2
-20
-91% -$2.17K ﹤0.01% 7380
2016
Q2 		$3K Buy
+22
New +$2.52K ﹤0.01% 6823

Other funds holding VTGN

CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
LM
Luminus Management Houston, Texas $146M AUM 27.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Bank of America's VTGN Position: Q2 2026 in Review

Bank of America opened a new position in VistaGen Therapeutics (VTGN) in Q2 2026: 16,570 shares worth $3.75K. The stake represents ﹤0.01% of the portfolio and ranks #5657 among its holdings. This is a return to the name: Bank of America previously reported a position in VTGN as recently as Q4 2025.

Bank of America first reported a position in VTGN in Q2 2016 and has held it in 23 quarters since. The position peaked at $1.04M in Q4 2021. 48 funds tracked by Wall St. Rank hold VTGN as of Q2 2026.

  • Bank of America held 16,570 shares of VistaGen Therapeutics worth $3.75K as of Q2 2026.
  • VistaGen Therapeutics was a new Bank of America position in Q2 2026.
  • VistaGen Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q2 2026, its #5657 holding.
  • Bank of America first reported a position in VistaGen Therapeutics in Q2 2016 and has held it in 23 quarters since.
  • Bank of America's VistaGen Therapeutics position peaked at $1.04M in Q4 2021.
  • 48 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2026.

Based on Bank of America's 13F filing for Q2 2026, filed 14 Aug 2026.